Lunit’s AI Platform SCOPE to Present Promising Cancer Treatment Response Predictions at ESMO 2025
Table of Contents
Leveraging the power of artificial intelligence, Lunit’s biomarker platform, Lunit SCOPE, is poised to unveil groundbreaking research predicting immunotherapy responses across multiple cancer types at the European Society of Medical Oncology (ESMO) 2025, held in Berlin, Germany, from September 17th to 21st.
Lunit, a leading medical AI company, announced on Thursday that it will present data from three studies demonstrating the potential of its AI technology to personalize cancer treatment strategies. According to a company release, the research focuses on predicting treatment response in kidney cancer, lung cancer, and colorectal cancer.
“At this ESMO, Lunit announces results confirming through data that AI can be linked to improved survival of actual patients,” stated a senior official. “In particular, as it has been proven in different cancer types such as colorectal cancer, renal cell cancer, and non-small cell lung cancer, the Lunit Scope is expected to become a key tool that can present customized treatment strategies in various cancers.”
AI-Powered Biomarker for Colorectal Cancer
One key presentation will detail the results of a study predicting the response to the immunotherapy drug atezolizumab (Tecentriq) in patients with colon cancer. This research, a collaboration with the oncology team led by Professor Chiara Cremolini at the University of Pisa in Italy, centers on developing a biomarker to predict treatment outcomes.
The study investigates the addition of atezolizumab to a combination therapy of the chemotherapy drug FOLFOXIRI (folpirinox) and the VEGF inhibitor bevacizumab (Avastin) for patients with normal mismatch reparative metastatic colorectal cancer (pMMR mCRC). This approach aims to identify patients most likely to benefit from this specific treatment regimen.
Expanding Applications in Kidney and Lung Cancer
Beyond colorectal cancer, Lunit SCOPE is also being evaluated for its ability to determine treatment strategies in first-line kidney cancer. The research presented at ESMO 2025 will focus on the feasibility of using AI immunophenotyping to guide clinical decisions.
Furthermore, a prospective, multicenter study conducted in Japan will showcase research on biomarkers predicting treatment response in lung cancer. This study highlights the platform’s potential for broader application across diverse patient populations and cancer subtypes.
The advancements presented by Lunit at ESMO 2025 underscore the growing role of artificial intelligence in oncology, offering the promise of more precise and effective cancer treatments. While full details of the studies are currently limited to paid members, the initial findings suggest a significant step forward in personalized cancer care.
.
